Stocks · News reference

ADC Therapeutics shares are trading lower after the company reported mixed Q2 financial results.

Aug 13, 2026, 6:14 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGAROct 13, 2026, 10:26 AMSEC EDGAR
8-K filing — ADC Therapeutics SA (ADCT)
Filed: 2026-10-13 AccNo: 0000950103-26-015465 Size: 808 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
ADCT
BenzingaOct 8, 2026, 1:07 PMBenzinga Newsdesk
ADC Therapeutics Announces $86.6M Pipe Financing For 12.9M Shares At $1.42/Share And Warrants To Purchase 48.1M Shares At $1.32/Warrant; Secures Loan And Royalty Amendments
ADCT
BenzingaAug 17, 2026, 1:41 PMBenzinga Newsdesk
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.
ADCT